Raltegravir use and outcomes among children and adolescents living with HIV in the IeDEA global consortium

INTRODUCTION: As integrase inhibitors become available in low‐ and middle‐income countries (LMICs), they offer the potential to expand extremely limited treatment options available to children and adolescents. In LMICs, only small numbers have used raltegravir, primarily as part of third‐line regime...

Descripción completa

Detalles Bibliográficos
Autores principales: Patten, Gabriela, Puthanakit, Thanyawee, McGowan, Catherine C, Wools‐Kaloustian, Kara, Hazra, Rohan, Pinto, Jorge A, Machado, Daisy, Succi, Regina, Sohn, Annette H, Rabie, Helena, Musick, Beverly, Davies, Mary‐Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387110/
https://www.ncbi.nlm.nih.gov/pubmed/32722897
http://dx.doi.org/10.1002/jia2.25580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387110/
https://www.ncbi.nlm.nih.gov/pubmed/32722897
http://dx.doi.org/10.1002/jia2.25580

Ejemplares similares